The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr.
The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with ...
Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback